MedTrace Logo

Platelet-rich Plasma(PRP) Injection in ED

NCT05241964 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-02-16

No results posted yet for this study

Summary

RPR contains rich-in growth factors and has the properties of helping tissue regeneration and nerve repair. In theory, it is possibility of curing ED.

Conditions

Interventions

BIOLOGICAL

PRP

4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • I-Ni Chiang, MD · Taipei Veteran General hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2022-09-22
Completion
2022-11-29

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05241964 on ClinicalTrials.gov